Researchers still found 'excellent' survival rates for both primary, secondary disease
by Tham on Mon Apr 20, 2009 12:00 AM
NSCLC - Cetuximab (Erbitux) with Erlotinib (Tarceva), other drugs or radiation. The first looks the most promising.Recruiting :http://clinicaltrials.gov/ct2/show/NCT00408499 http://clinicaltrials.gov/ct2/show/NCT00842712 http://clinicaltrials.gov/ct2/show/NCT00673738 http://clinicaltrials.gov/ct2/show/NCT00343291 http://clinicaltrials.gov/ct2/show/NCT00492206 Recruiting later.http://clinicaltrials.gov/ct2/show/NCT00820755
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
Do you use smart phone apps?
Take our short survey on hospital smart phone apps.
We care about your feedback. Let us know how we can improve your CancerCompass experience.